The role of dopamine D1 and D2 receptor subtypes in the regulation, in vivo, of the somatostatin (SRIF) receptoreffector system in rat frontoparietal cortex was investigated. The D1-receptor agonist SKF 38393 (4 mg/kg) or the D2-receptor agonist bromocriptine (2 mg/kg), administered intraperitoneally to rats, increased the number of SRIF receptors without altering the affinity constant, an effect antagonized by both SCH 23390 (0.25 mg/kg) and raclopride (5 mg/kg), D1 and D2 receptor antagonists, respectively. These antagonists alone had no effect on [ 125 I]Tyr 3 octreotide binding to its receptors. No change in binding was detected when the dopamine agonists were added in vitro. Basal adenylyl cyclase (AC) activity was increased by SKF 38393 treatment and decreased by bromocriptine. Octreotide (SMS 201-995)-mediated inhibition of basal and forskolin-stimulated AC was increased by SKF 38393 or bromocriptine treatment. In frontoparietal cortical slices, basal inositol-1,4,5-triphosphate (IP 3 ) levels were decreased by bromocriptine treatment but were unaffected by SKF 38393. SMS 201-995 increased the IP 3 accumulation in control, SKF 38393-, and bromocriptine-treated rats. Insofar as SRIF and dopamine appear to be involved in motor regulation and could well modulate somatosensory functions in frontal and parietal cortex, respectively, heterologous receptor regulation may have important repercussions regarding the control exerted by these neurotransmitters on frontal and parietal cortical function in the intact animal. J. Neurosci. Res. 62:91-98, 2000. 
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3 octreotide binding to its receptors. No change in binding was detected when the dopamine agonists were added in vitro. Basal adenylyl cyclase (AC) activity was increased by SKF 38393 treatment and decreased by bromocriptine. Octreotide (SMS 201-995)-mediated inhibition of basal and forskolin-stimulated AC was increased by SKF 38393 or bromocriptine treatment. In frontoparietal cortical slices, basal inositol-1,4,5-triphosphate (IP 3 ) levels were decreased by bromocriptine treatment but were unaffected by SKF 38393. SMS 201-995 increased the IP 3 accumulation in control, SKF 38393-, and bromocriptine-treated rats. Insofar as SRIF and dopamine appear to be involved in motor regulation and could well modulate somatosensory functions in frontal and parietal cortex, respectively, heterologous receptor regulation may have important repercussions regarding the control exerted by these neurotransmitters on frontal and parietal cortical function in the intact animal. J. Neurosci. Res. 62:91-98, 2000. Several studies have indicated selective localization of somatostatin (SRIF)-like immunoreactivity in deep cortical layers (Finley et al., 1981; Hendry et al., 1984; Johansson et al., 1984) . Cerebral cortical membranes contain one of the largest SRIF receptor concentrations (Srikant and Patel, 1981; Reubi and Maurer, 1985; Krantic et al., 1990) . The effects of SRIF on the central nervous system (CNS) are mediated by G-protein-coupled receptors (Law et al., 1991) . Following the cloning of the genes encoding for at least five SRIF receptor subtypes, labelled SSTR1-5 , it became evident that the SS1/SRIF-1 class comprises SSTR2, SSTR3, and SSTR5 receptors, whereas the SS2/SRIF-2 class consists of SSTR1 and SSTR4 receptors (Brunns et al., 1995) . All these receptors mediate inhibition of adenylyl cyclase (AC) activity (Patel, 1999) whereas SSTR2 and SSTR5 also couple to phospholipase C (PLC) in CNS. The deeper layers of cortical areas, rich in SRIF and its receptors, have been shown to contain an innervation of dopamine (DA)-positive nerve terminals originating from the ventral midbrain tegmentum (Descarries et al., 1987) . The dopaminergic input to the frontal and parietal cortices plays an important role in sensorimotor functions (Gaspar et al., 1995) , such as SRIF (Welker, 1971; Finley et al., 1981; Epelbaum et al., 1982) . DA exerts its action via dopamine D1-like (D1 and D5) and D2-like (D2, D3, and D4) receptors, although the neural circuits involved are not completely understood (Civelli et al., 1993) . Several studies suggest that SRIF and DA receptors are colocalized on neuronal subgroups (Chneiweiss et al., 1985a) . Behavioral studies have shown the importance of an intact somatostatinergic system in the full expression of DA-mediated behaviors (Lee et al., 1988) . Although interactions between SRIF and dopaminergic neurons are well documented (Pérez-Oso et al., 1989; Salin et al., 1990; Shog-monian and Chesselet, 1991; Engber et al., 1992; De los Frailes et al., 1993; Pérez-Oso and Arilla, 1993; Rodríguez-Sánchez et al., 1997) , there are no reports concerning the influence of D1 and D2 dopamine receptors on the SRIF receptor-effector system located in the cerebral cortex.
Because the deeper cortical layers are enriched in SS1/SRIF1 receptor sites (Krantic et al., 1990 ) and the stable SRIF octapeptide SMS 201-995 (octreotide) is selective for the SS1/SRIF1 site (Krantic et al., 1992; Hoyer et al., 1994) , we have used octreotide and its tyrosine analogue, code named SDZ 204-090, to study the effect of SKF 38393, a D1-receptor agonist, and bromocriptine, a D2-receptor agonist, on the specific binding of [ 125 I]Tyr 3 octreotide to its receptors and on the ability of SMS 201-995 to inhibit basal and forskolin (FK)-stimulated AC activity in rat frontoparietal cortical membranes. In addition, the effect of these compounds on SMS 201-995-stimulated inositol 1,4,5-triphosphate (IP 3 ) accumulation in the rat frontoparietal cortex was examinated. The effects of pretreatment with the D1-receptor antagonist, SCH 23390, or the D2-receptor antagonist, raclopride, on the above-cited parameters were also evaluated.
MATERIALS AND METHODS

Materials
The peptide SMS 201-995 and its tyrosine analogue SDZ 204-090 were kindly donated by Sandoz (Basel, Switzerland); carrier-free Na 125 I (IMS 300; 100 mCi/ml) was purchased from the Radiochemical Centre (Amersham, U.K.); SKF 38393 and SCH 23390 were purchased from Research Biochemicals Inc. (Natick, MA); raclopride was kindly donated by Astra Ifesa (Barcelona, Spain); bromocriptine, bacitracin, BSA, forskolin, phenylmethylsulphonyl fluoride, GTP, and 3-isobutyl-1-methylxanthine were purchased from Sigma (St. Louis, MO); IP 2, 3, 4, 5, ) were from Calbiochem (San Diego, CA); [ 3 H]IP 3 and [ 3 H]cAMP were purchased from DuPont (Boston, MA). All other reagents were of the highest purity commercially available.
Experimental Animals
All experimental procedures conform to the guidelines established by the Animal Care and Use Committee of our University and were accordingly approved prior to implementation. The animals used in this study were male Wistar rats with an average weight of 200 -250 g. Rats were maintained on a 12-hr light-dark cycle (lights on 07:00 -19:00 hr) and allowed free access to food. The rats were injected intraperitoneally (i.p.) with 4 mg/kg of SKF 38393 dissolved in saline or 2 mg/kg of bromocriptine dissolved in 0.5 ml ethanol 70%-0.14 M NaCl (1:1.5 v/v). In other experimental groups, SCH 23390 (0.25 mg/ kg, i.p.) or raclopride (5 mg/kg, i.p.), dissolved in saline, was administered 30 min before their corresponding agonist, SKF 38393 (4 mg/kg, i.p.) or bromocriptine (2 mg/kg, i.p.), respectively. A third group of animals was injected i.p. with 0.25 mg/kg SCH 23390 or 5 mg/kg raclopride. Drug doses were selected according to the effective doses reported in previous studies (Augood et al., 1991; Rodríguez-Sánchez et al., 1997) . Control animals selected for each group were injected with equivalent volumes of the corresponding vehicle. Rats were sacrificed by decapitation 3 hr after the last drug injection (Engber et al., 1992) . The brain was rapidly removed, and the frontoparietal cortex was dissected over ice as previously outlined (Glowinski and Iversen, 1966) .
Iodination of SDZ 204-090
The stable SRIF analogue SDZ 204-090, which has previously been demonstrated to bind specifically to SRIF receptors with high affinity (Reubi, 1985) , was radiodinated according to a technique described for other SRIF-related peptides (Antoniotti et al., 1984) . Briefly, 10 l of a Na 125 I solution (1 mCi) were added to 10 g of SDZ 204-090 dissolved in 50 l of a 0.25 M sodium phosphate buffer, pH 7.5. Subsequently, five additions of 5 l of chloramine-T (0.5 g/l in water) were carried out, with 10 sec intervals between each addition. Finally, 120 l of a tyrosine solution (2 g/l in phosphate buffer 0.5 M/NaOH 0.2 M) were added. The mixture was loaded onto a Bondapak C18 column (30 ϫ 0.39 cm i.d.), and, with a Waters Associates liquid chromatograph, the tracer was eluted at a flow of 1 ml/min in a preprogrammed nonlinear gradient rising from 20% to 80% (v/v) acetonitrile in 0.25 M triethylammonium phosphate, pH 3.5, in 40 min. The tracer was eluted after 15 min. Radioactivity in the fractions containing the tracer was found to be 900 Ci/mmol.
Binding Assay
Rat frontoparietal cortical membranes were prepared as previously described (Reubi, 1985) . Membrane protein was quantified by a technique previously described (Lowry et al., 1951) , using BSA as a standard. Specific SMS 201-995 binding was measured according to a modified method (Czernik and Petrack, 1983) . Briefly, frontoparietal cortical membranes (0.036 mg protein/ml) were incubated in 250 l of a medium containing 50 mM Tris-HCl buffer, pH 7.5, 5 mM MgCl 2 , 0.2% (w/v) BSA, and 0.1 mg/ml bacitracin, with 200 pM [ 125 I]Tyr 3 octreotide in either the absence or the presence of 0.01-100 nM of SMS 201-995. After incubation for 90 min at 25°C, the free radioligand was separated from the bound radioligand by centrifugation at 11,000g for 2 min, and the resultant pellet was counted for radioactivity in a Kontron ␥-counter. Nonspecific binding was obtained from the amount of radioactivity bound in the presence of 10 Ϫ7 M unlabelled SMS 201-995 and represented 20% of the binding observed in the absence of unlabelled peptide. This nonspecific component was subtracted from the total bound radioactivity to obtain the corresponding specific binding.
Adenylyl Cyclase Assay
AC activity was measured as previously reported (Houslay et al., 1976) , with minor modifications. Briefly, frontoparietal cortical membranes (0.036 mg/ml) were incubated with 1.5 mM ATP, 5 mM MgSO 4 , 10 M GTP, an ATPregenerating system (7.5 mg/ml creatine phosphate and 1 mg/ml creatine kinase), 1 mM 3-isobutyl-1-methylxanthine, 0.1 mM phenylmethylsulphonyl fluoride, 1 mg/ml bacitracin, 1 mM EDTA, and test substances (10 Ϫ5 M SMS 201-995 or 10 Ϫ5 M FK) in 0.1 ml of 0.025 M triethanolamine/HCl buffer, pH 7.4. After a 15 min incubation at 30°C, the reaction was stopped by heating the mixture for 3 min. After getting it cool, 0.2 ml of an alumina slurry (0.75 g/ml in triethanolamine/HCl buffer, pH 7.4) were added, and the resulting suspension was centrifuged at 3,000g. The supernatant was removed to the cAMP assay as previously described (Gilman, 1970) .
IP 3 Analyses
Cross-chopped frontoparietal cortical slices (250 ϫ 250 m) were prepared from male Wistar rats (200 -250 g) and preincubated for 45 min at 37°C in Krebs bicarbonate buffer (118 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl 2 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 11.7 mM glucose, 10 mM HEPES), pH 7.4, saturated with O 2 /CO 2 (95/5%), with buffer replacement and gassing every 15 min (Challiss et al., 1988) . Slices were allowed to sediment, and 50 l of packed slices were added to tubes containing 200 l of Krebs buffer and 20 l of 1.5 mM LiCl. The samples were gassed regularly, capped, and incubated. SMS 201-995 (10 Ϫ7 M) in a volume of 30 l was subsequently added to these tubes. Incubation was terminated by addition of 500 l of 0.5 M trichloroacetic acid (TCA). Acidified samples were left on ice for 15 min and subsequently centrifuged for 15 min at 1,800g. To remove TCA, the supernatants were washed five times with 1.25 ml of water-saturated diethyl ether, and, finally, 200 l of 50 mM Tris-HCl, pH 8.4, were added. The protein concentration in the tissue pellets was determined as previously described (Lowry et al., 1951) .
The specific binding of [ 3 H]IP 3 to a preparation of bovine cerebellum membranes was used as a radioreceptor assay to determine the IP 3 concentration in these slices, according to the method previously described (Bredt et al., 1989) . Bovine cerebellar membranes were prepared by homogenizing bovine cerebella in a cold buffer A (50 mM Tris-HCl, 1 mM EDTA and 1 mM 2-mercaptoethanol), pH 7.7, to obtain a protein concentration of 4 mg/ml (Challiss et al., 1988) . These membranes (50 g/tube) were added to Eppendorf tubes containing 25 l of [ 3 H]IP 3 (5 nCi/tube) and 50 l of unknown or standard samples containing IP 3 (0.005 M-5 M in buffer A, pH 8.6) or IP 6 (1% w/v in buffer A, pH 8.6) to define nonspecific binding. All tubes were incubated for 10 min at 4°C. Separation of bound and free IP 3 was achieved by centrifugation at 10,000g for 5 min. After aspiration of the supernatant, 50 l of 0.15 M NaOH were added to each tube, and the pellet was dissolved by shaking. The radioactivity was determined by liquid scintillation spectrometry. The IP 3 content was determined by interpolating the inhibition of [ 3 H]IP 3 binding on a calibration curve with known amounts of IP 3 . Nonspecific binding was 13% of the total binding.
Data Analysis
The computer program LIGAND (Munson and Rodbard, 1980 ) was used to analyze the binding data. The use of this program enabled us to select receptor models that best fit a given set of binding data. The same program was also used to present data in the form of Scatchard plots (Scatchard, 1949) and to compute values for receptor affinity (Kd) and density (Bmax) that best fit the sets of binding data for each rat. Statistical comparisons of all the data were carried out by one-way analysis of variance (ANOVA) and the Student's Newman-Keuls test.
Means among groups were considered significantly different when P values were Ͻ0.05. Each experiment was performed in duplicate.
RESULTS
Stoichiometric experiments were performed on rat frontoparietal cortical membranes using a fixed concentration of [ (Figs. 1, 2, right panel) . Interpretation of these data with the LIGAND computer program (Munson and Rodbard, 1980 ) resulted in the best fit for a model with one type of SRIF receptor. Frontoparietal cortical membranes from SKF 38393-or bromocriptine-treated rats exhibited significant increases in the maximum SRIF binding capacity compared to controls. However, the corresponding Kd values remained unchanged after treatment. Under specified conditions, the effect of the D1 agonist was similar to that of the D2 agonist (Tables I, II vitro addition of SKF 38393 or bromocriptine to the incubation medium at the time of the binding assay had no effect on frontoparietal cortical SRIF receptors (data not shown). The signaling pathways coupled to SRIF receptors were evidenced by the ability of SMS 201-995 to inhibit AC activity and to stimulate accumulation of IP 3 . We examined the inhibitory effect of increasing concentrations of SMS 201-995 on basal and FK (10 Ϫ5 M)-stimulated AC activity in frontoparietal cortical membranes of control rats. The somatostatinergic inhibition of both basal and FK-stimulated AC activity was significant only for the maximal dose tested (10 Ϫ5 M; Fig. 3 ). Because the SMS 201-995 concentration necessary to achieved inhibition of AC activity was 10 Ϫ5 M, this concentration was used in a subsequent detailed study of basal and FK-stimulated AC activity in control rats and rats treated with SKF 38393 or bromocriptine. The effect of SKF 38393 or bromocriptine on basal and FK-stimulated AC activity was markedly increased or decreased, respectively, in frontoparietal cortical membranes compared to controls (Table III) . In the SKF 38393 or bromocriptine groups, the degree of SMS 201-995-mediated enzyme inhibition of both basal and FK-stimulated AC activity was significantly higher than in the control groups. This SMS 201- 995 effect was significantly higher in the SKF 38393-treated animals than in the bromocriptine-treated animals (Table III) . To test whether the observed changes were related to modifications in AC expression, we measured the response of the enzyme to the diterpene FK, which is assumed to act directly on the catalytic subunit. No significant differences were detected in the -fold FK stimulation over basal AC activity between the controls and the SKF 38393-or bromocriptine-treated group.
The treatment with SKF 38393 did not modify basal IP 3 levels, whereas bromocriptine decreased IP 3 accumulation in frontoparietal cortical slices (Fig. 4) . SMS 201-995 significantly increased IP 3 accumulation in frontoparietal cortical slices from control, SKF 38393-and bromocriptine-treated rats (Fig. 4) .
DISCUSSION SKF 38393 and Bromocriptine Increased the Number of SRIF Receptors
The data reported here suggest that D1-and D2-receptors are involved in the increase of functional SRIF receptors in the rat frontoparietal cortex. This was manifested by an increase in the ability of SMS 201-995 to inhibit FK-stimulated AC activity in the rats treated with SKF 38393 or bromocriptine. The fact that SKF 38393 and bromocriptine increase the functional activity of SRIF receptors seems to be a result of activation of D1 and D2 receptors, respectively, in that the effect of SKF 38393 on SRIF binding was effectively antagonized by the D1-specific antagonist SCH 23390, whereas the effect of bromocriptine was abolished by the D2-specific antagonist raclopride. Furthermore, the in vitro addition of the D1 or D2 DA agonist, SKF 38393 or bromocriptine, respectively, to frontoparietal cortical membranes from untreated rats did not affect the SRIF binding parameters. The present result is in agreement with the result that the blockage of dopaminergic transmission with haloperidol (3 days) did not affect the number of SRIF receptors in rat brain (Pérez-Oso et al., 1989) . The mechanism by which dopaminergic stimulation increases [ 125 I]Tyr 3 octreotide binding in the frontoparietal cortex is not clear. It has been demonstrated that sulpiride increases dopaminergic neurotransmision (Elliot et al., 1977) . Our research group has demonstrated that sulpiride significantly decreased the SRIF-like immunoreactivity levels in the frontoparietal cortex (Rodríguez-Sánchez et al., 1994) . Therefore, the decrease in the SRIF-like immunoreactivity content could explain the increase in Bmax observed. On the other hand, it is unknown whether this increase in Bmax is secondary to that of the dopaminergic agonists on other neurotransmitter systems.
Effects of SKF 38393 and Bromocriptine on AC Activity
Stimulation of D1 receptors activates AC, whereas D2 receptor stimulation either inhibits or does not stim- ulate the activity of this enzyme (Kebabian et al., 1984; Battaglia et al., 1985; Onali et al., 1985; Weiss et al., 1985) . Therefore, our results seem to be in agreement with the above-mentioned studies. The -fold FK stimulation of AC activity over basal activity was similar in frontoparietal cortical membranes of control and SKF 38393-or bromocriptine-treated rats, indicating that the AC catalytic subunit was intact.
Basal and FK-stimulated AC activity was inhibited by SMS 201-995 in all experimental groups analyzed, which is in agreement with other authors (Markstein et al., 1989) . A concentration of 10 Ϫ5 M of SMS 201-995 was required to produce this inhibition. A concentration of 10 Ϫ4 M of SRIF was used by other authors in their studies on the effect of SRIF on AC activity in rat and human brain (Schettini, 1991) . The high affinity of the SRIF receptors is incompatible with the SRIF concentration required to reduce AC activity. In view of the different response of neuronal and glial cells to SRIF-mediated inhibition of AC (Chneiweiss et al., 1985a,b; Colás et al., 1992) , it is possible that the cell heterogeneity of the present preparations is responsible for the high SMS 201-995 concentration necessary to achieve AC inhibition. In addition, the synaptic SRIF concentration is, so far, unknown. SMS 201-995-mediated inhibition of basal and FK-stimulated AC activity was greater in rats treated with SKF 38393 or bromocriptine than in the control animals. This increased AC sensitivity to SMS 201-995 induced by both dopaminergic agonists may be a consequence of the rise in the number of SRIF receptor observed. 3 Our results showing that D1-like DA receptor stimulation had no effect on IP 3 formation, whereas stimulation of D2-like DA receptors decreased the IP 3 formation, are in agreement with previous studies (Pizzi et al., 1988) . However, there are many contradictory reports in the literature regarding the effects of D1 DA receptors on inositol phosphate metabolism. Studies in anterior pituitary cells also suggest that D2 receptor stimulation indirectly suppresses inositol phospholipid hydrolysis (Simmonds and Strange, 1985; Journot et al., 1987) . However, Kelly et al. (1988) were unable to observe activation or inhibition of striatal phosphoinositide metabolism with either DA or selective D1 and D2 DA receptor agonists. The discrepancy between our findings and the earlier reports possibly stems from differences in the drug dose used and the time points at which the observations were made. SMS 201-995 significantly increased IP 3 accumulation in frontoparietal cortical slices of control rats in agreement with other studies (Lachowicz et al., 1994; Muñoz-Acedo et al., 1995) . The SMS 201-995 concentration eliciting IP 3 accumulation was about two orders of magnitude higher than the corresponding binding. This apparent discrepancy can be explained by the different experimental conditions used in each type of experiment. Our binding studies were obtained at equilibrium after an incubation of 90 min at 25°C. In contrast, IP 3 accumulation is a transient process that must be measured 15 sec after exposing brain slices to SRIF. Therefore, this very short period may not be sufficient to reach binding equilibrium.
Effects of SKF 38393 and Bromocriptine on IP
The dopamine agonists SKF 38393 and bromocriptine enhance the ability of SMS 201-995 to inhibit basal and FK-stimulated cAMP accumulation. However, no differences in SMS 201-995-stimulated phosphoinositides turnover were detected. Previous studies have demonstrated uncoupling of receptors from G proteins. In this regard, Ungar et al. (1993) have demonstrated that estrogen uncouples ␤-adrenergic receptor from the G protein. Therefore, the differences found between the SMS 201-995-induced inhibition of cAMP accumulation and the SMS 201-995-induced stimulation of IP 3 accumulation could be due to an uncoupling of the receptor from Gq proteins and/or PLC.
The dopaminergic input to the frontal cortex has an important role in motor and cognitive functions (Gaspar et al., 1995) . These effects are mediated by both D1 and D2 DA receptors (Civelli et al., 1993) . In caudate putamen, nucleus accumbens, olfactory tubercle, substantia nigra, entopeduncular nucleus, zona incerta, and region of the ventral internal capsule, D1 receptor subtype was found at greater density than D2 receptor subtypes. In the olfactory nerve layer, a higher density of D2 receptor sybtypes was found in comparison to D1 receptor subtype. In the ventral tegmental area, the presence of D2 receptor subtype was not detected (Boyson et al., 1986) . Moderate densities of mRNA D1 receptor sites are seen in deep layers of the frontal and parietal cortices, with light diffuse labeling observed in more superficial layers (Mansour et al., 1990) . Dense levels of D2 receptor mRNA are found in the layer I and in layers II and III of the frontal and parietal cortices. However, the deeper layers (V and VI) of frontal and parietal cortices show moderate to low levels of D2 receptor mRNA (Mansour et al., 1990) . D1 and D2 receptors have been described in different populations of efferent pyramidal neurons in the rat frontal cortex (Mansour et al., 1990; Mansour and Watson, 1995) . The expression of D1 and D2 receptor genes is specific for different categories of pyramidal neurons (Gaspar et al., 1995) . Recently, the presence of SSTR1, SSTR2, SSTR3, and SSTR5 receptors in deep layers of frontal and parietal cortex has been demonstrated (Bruno et al., 1993; Kong et al., 1994; Pérez and Hoyer, 1995) . In addition, the expression of mRNA for SRIF receptor subtypes SSTR2 and SSTR3 has been found on pyramidal cells in the cited brain areas (Kong et al., 1994; Pérez and Hoyer, 1995) . The confirmed presence of DA terminals (Descarries et al., 1987) and SRIF interneurons (Finley et al., 1981; Johansson et al., 1984) with its specific receptors (Mansour et al., 1990; Bruno et al., 1993; Kong et al., 1994; Mansour and Watson, 1995; Pérez and Hoyer, 1995) in the deepest layer of the frontal motor areas and parietal somatosensory areas implies a role in the processing sensoriomotor information (Welker, 1971; Gaspar et al., 1995) . Taken together, the present results support the notion that the dopaminergic system regulates the binding of SRIF to its specific receptors in the rat frontoparietal cortex.
